Showing results (111-120 of 280) with videos related to

Sort By:
Pageof 28
Blood|June 27, 2009
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)Ivan M Borrello, Hyam I Levitsky, Wendy Stock, et al.
Leukemia Research|December 3, 2019
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trialElias Jabbour, Nicola Gökbuget, Anjali Advani, et al.
Leukemia Research|September 22, 2019
Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemiaDaniel J DeAngelo, Alison R Walker, Richard F Schlenk, et al.
Oncoimmunology|November 22, 2012
Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patientsAna Brusic, Ursula Hainz, Martha Wadleigh, et al.
Leukemia Research|December 28, 2022
Intensity of induction regimen and outcomes among adults with Ph+ALL undergoing allogeneic hematopoietic stem cell transplantationHari S Raman, Se Eun Kim, Daniel J DeAngelo, et al.
Blood Advances|January 4, 2018
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 studyDaniel J DeAngelo, Wendy Stock, Anthony S Stein, et al.
Blood Advances|November 15, 2024
Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemiaMarlise R Luskin, Shai Shimony, Julia Keating, et al.
American Journal of Hematology|January 10, 2019
Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicinElias Jabbour, Anjali S Advani, Matthias Stelljes, et al.
British Journal of Haematology|March 4, 2015
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 studyRonan T Swords, Harry P Erba, Daniel J DeAngelo, et al.
Blood Advances|July 11, 2023
Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trialsShai Shimony, Yael Flamand, Yannis K Valtis, et al.
Pageof 28